Key Takeaways
- President Trump visited a Mack Trucks (VOLV-B) facility in Pennsylvania to pivot his agenda toward the U.S. economy following an interim peace deal to end the war with Iran.
- The Trump administration is considering White House aide Heidi Overton to lead the Food and Drug Administration (FDA) as the agency faces a leadership void and internal turmoil.
- Senate Majority Leader John Thune and other GOP lawmakers are demanding a formal role in reviewing the Iran peace deal, citing concerns over a $300 billion development fund for Tehran.
- Bank of Canada Governor Tiff Macklem reported that Canadian inflation hit 3.2% in May, primarily driven by oil price shocks from the Iran conflict, though he noted no signs of "generalized inflation."
- A landmark bipartisan housing bill passed the Senate 85-5, aiming to increase supply and ban corporate investors from purchasing single-family homes.
Trump Pivots to Trade and Economy in Pennsylvania
President Donald Trump visited Macungie, Pennsylvania, on Tuesday to tout his protectionist trade agenda and shift the national conversation toward the U.S. economy. The visit to the Mack Trucks (VOLV-B) facility marks his first major public event since signing an interim agreement to end the war with Iran, a conflict that has significantly impacted global energy prices.
Trump’s focus on the economy comes as he seeks to mitigate political damage from high gasoline prices ahead of the November midterm elections. While the president emphasized a rebound in domestic manufacturing, recent polling shows only one-third of U.S. adults approve of his stewardship of the economy, with many still critical of his handling of the Iran crisis.
FDA Leadership Search Focuses on White House Aide
The White House is reportedly zeroing in on Heidi Overton, a deputy assistant to the president and medical doctor, to serve as the next FDA Commissioner. The agency has been without permanent leadership since Marty Makary resigned in May, leading to a wave of departures among senior career officials and regulatory uncertainty for the pharmaceutical industry.
Overton, a Johns Hopkins-trained physician, is seen as a candidate who could bridge the gap between the administration’s "Make America Healthy Again" agenda and the agency's scientific mission. However, her nomination may face complications depending on the support of HHS Secretary Robert F. Kennedy Jr., who has been critical of the FDA’s past performance.
GOP Unease Grows Over Iran Peace Terms
Despite the signing of a Memorandum of Understanding to end hostilities, Republican leadership in the Senate is expressing growing unease over the lack of transparency regarding the deal's specifics. Senate Majority Leader John Thune stated that Congress must have a say in the agreement, particularly regarding the $300 billion reconstruction fund allocated for Iran.
Critics, including Senator Ted Cruz, have labeled the financial incentives a "capitulation," comparing the package unfavorably to previous diplomatic efforts. The Senate recently approved a war powers resolution in a rare rebuke to the administration, signaling that the 60-day window for a final agreement will face intense legislative oversight.
Global Markets and Diplomatic Strains
In Canada, Governor Tiff Macklem noted that while inflation exceeded the 1-3% target range for the first time in over two years, the spike was "very concentrated in oil prices." Macklem expressed optimism that the U.S.-Iran detente would continue to lower crude prices, though he warned that food inflation remains a persistent concern for the Bank of Canada.
On the diplomatic front, Italian Prime Minister Giorgia Meloni called for a "return to normality" with the U.S. following a public spat with President Trump. The disagreement, sparked by Trump’s claims that Meloni "begged" for a photo at the G7 summit, had briefly threatened strategic ties and led to the cancellation of a high-level Italian diplomatic visit to Washington.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.